Abstract Section
Total Page:16
File Type:pdf, Size:1020Kb
Technologist Presentations A Note on 2018 Technologist Abstracts For the Technologist Abstract track, 35 scientifi c papers have been accepted for presentation at the 65th SNMMI Annual Meeting at the Philadelphia Convention Center, Philadelphia, PA. The Program Committee for the SNMMI Technologist Section (SNMMI-TS) will be hosting 5 oral sessions to present these scientifi c papers, to be held on Sunday, June 24, and Monday, June 25; refer to the 2018 Annual Meeting Program Book for specifi c times and locations. Each oral session is 90 minutes in duration and includes up to seven 12-minute presentations per session. For the Technologist Abstract track, 70 scientifi c posters have been accepted for presentation. The SNMMI-TS Program Committee will be hosting a Technologist “Meet the Author” poster session, scheduled for Monday, June 25, from 3:00PM-4:30PM. The posters will be on display and available for viewing by attendees in the Poster Hall (Exhibit Hall C). SNMMI Abstracts Online: Accepted abstracts for the 65th SNMMI Annual Meeting are citable and searchable by visiting the JNM website at: http://jnm.snmjournals.org/ SUNDAY SESSIONS value of this promising approach. Interesting innovation arise from the application of fl uorinated PSMA-ligands yielding F18-specifi c advantages compared to Ga68 (e.g. longer Half-life, lower positron range, higher Tech Papers I: Clinical PET production of activity). Authors listed for this abstract reported no relevant fi nancial disclosures. Moderator: Mary Beth Farrell, MS, CNMT, NCT, FSNMMITS Co-Moderator: April Mann 2102 The evaluation of the spatial resolution of 11C-, 18F- and 64Cu-PET 2101 Technologists Track images on a clinical PET/CT scanner using Monte Carlo Simulation and phantom examination. Saki Kimoto1, Naoki Hashimoto1, Ayano Ga68PSMA PET/MRI a revolution to detect primary prostate cancer. Shoji1, Yuji Tsutsui1,2, Kazuhiko Himuro2, Shingo Baba, MD, PhD2, Sylvia Schachoff1, Tobias Maurer2, Stephan G. Nekolla1, Markus Akihiko Takahashi1, Masayuki Sasaki, MD, PhD3; 1Kyushu University, Schwaiger, MD1, Wolfgang A. Weber, MD1, Matthias Eiber, MD1; Fukuoka, Japan, 2Kyushu University Hospital, Fukuoka, Japan, 3Dept Rad 1Nuclear Medicine, TU Munich, Munich, Germany, 2Department of Sci Sch of Health Sci Kyushu Univ, Fukuoka, Japan. (1762) Urology, Munich, Germany. (2095) Purpose: The goal of this study was to evaluate the spatial resolution of Aim: Defi ne a PET/MR study protocol using Ga68-PSMA for patients PET images on PET/CT scanner using 11C (0.960 MeV), 18F (0.633 MeV) with elevated PSA value and negative prostate biopsies but high suspicion and 64Cu (0.650 MeV) by Monte Carlo Simulation (MCS) and phantom of tumor. examination. Methods: For patients with suspected primary prostate cancer, Ga68- Materials and Methods: In MCS, spherical sources (diameter: 0.7 mm) PSMA-PET MRI is a novel and promising imaging technique. Ga68- of 11C, 18F and 64Cu were generated and 10, 000 annihilation positions of PSMA is a new PET tracer that targets the active center of the extracellular positrons were recorded. The full width at half maximum (FWHM) and the domain of PSMA - a protein with high expression in prostate cancer but full width at tenth maximum (FWTM) were measured from the distribution low anywhere else in the body. In our clinical routine 45 % of Ga68-PSMA function of the positron annihilation positions, and the FWHM to FWTM PET/MR examinations are for primary prostate cancer with half of them ratio (FWHM/FWTM) was then calculated. In the phantom examination, in patient with increased PSA and prior negative prostate biopsies. Our the PET data were acquired using a Biograph mCT scanner. The point PET/MRI protocol combines the advantages of molecular information from sources (inner diameter: 0.7 mm) with 11C, 18F and 64Cu were placed at PET with a state of the art multi-parametric MRI of the prostate (T2w 3D, transaxial positions (0, 1) cm. The radioactivity concentration was 21.2 diffusion, dynamic contrast-enhanced sequence). The examination takes MBq/mL. The data were acquired in the three-dimensional list mode and about 35 minutes and requires an optimal preparation of the patients (e.g. then were reconstructed using fi ltered back projection. A Gaussian fi lter MRI contraindications, laboratory values such as PSA and creatinine). was not used. The image matrix was 400×400 and the slice thickness was Results: Ga68-PSMA PET imaging allows direct visualization of PSMA- 5 mm. The FWHM, the FWTM and the FWHM/FWTM were calculated avid tumor lesions independent of metabolism - thus regenerative and from the PET images. infl ammatory change have hardly any infl uence). The soft-tissue contrast Results: On MCS, the FWHM/FWTM of 11C, 18F and 64Cu were 0.284, of MRI-sequences and their anatomical resolution in combination with 0.396 and 0.396, respectively. 11C, which has the highest positron energy, the PET-signal, clearly help to diagnose prostate cancers, especially in the showed the smallest FWHM/FWTM. On the phantom examination, the transition zone which is diffi cult for MRI alone. The information of our FWHM/FWTM of 11C, 18F and 64Cu were 0.439±0.03, 0.423±0.03 and Ga68-PSMA PET/MR dataset is used in by local urologists to perform 0.444±0.04, respectively. There were no signifi cant differences among the PET-MRI-Ultrasound-Fusion guided biopsies. This helps to increase cancer FWHM/FWTM of 11C, 18F and 64Cu. detection rate in a diffi cult patient population. Conclusions: In conclusion, the positron energy was considered to Summary: Ga68-PSMA PET/MR is a novel method to detect prostate infl uence the theoretical spatial resolution of positron imaging in MCS, but cancer in men with prior negative biopsies but persistently elevated PSA- no such infl uence was observed on the clinical PET images. Therefore, the values. Combining PET with MRI using PET/MRI rather than PET/CT spatial resolution of clinical PET images seems to be too low to measure allows integral assessment of functional and molecular information and differences in positron energy among 11C, 18F and 64Cu. provide soft-tissue contrast to enable imaging guided biopsy. Based on our experience additional investigations are necessary to defi ne the exact Authors listed for this abstract reported no relevant fi nancial disclosures. 2018 TECHNOLOGIST SECTION ABSTRACTS 155 Technologists Track 2103 of CRP and ESR. Plasma PTX3 levels were also measured by enzyme- linked immunosorbent assay (ELISA) in all of the above patients. We have Evaluation of metabolic tumor volume using different image 1 introduced a new indicator named Ratio.V(Ratio.V = artery/liver * volum reconstruction algorithm on 18F-FDG PET image. Seok Hwan Yoon , of the lesion) as a quantitative indicator which considering the volum of Hong Jae Lee1, Gyeong Woon Noh1, Jae Sung Lee, PhD2, Jin Chul Paeng, 1 1 1 lesion measured in ture D mode. The Ratio(artery/liver) >1.0 was set as the MD, PhD , Keon Wook Kang, MD, PhD , Dong Soo Lee, MD, PhD , gold standard to determine the activity of arteritis, according to the previous June-Key Chung, MD, PhD1; 1Seoul National University Hospital, Seoul, 2 clinical studies. Korea, Republic of, Seoul National University, Seoul, Korea, Republic Results: 34 patients in TKA group were determined to be active by 18F- of. (1562) FDG PET/CT. The level of plasma PTX-3 in active TKA patients was signifi cantly higher than that in non-active TKA patients (3.56±0.54 v.s. Purpose: Recently, MTV(Metabolic tumor volume) has been used 1.15±0.09, p<0.05). PTX3 level was positively correlated with the Ratio.V as indices of the whole tumor FDG uptake on FDG PET image. but it (Spearman r=0.59,p<0.001). No signifi cant correlation were found between is infl uenced by image reconstruction. The purpose of this study was to the Ratio.V and the level of CRP or ESR (Spearman r=0.37 and 0.23, p evaluate the correlation of MTV applied different SUVmax threshold for =0.04 and 0.21). Under the guidance of 18F-FDG PET/CT, the specifi city different reconstruction algorithm on phantom and patient study. of PTX-3 diagnosis was 79.41% and the sensitivity was 87.10%, and the Methods: In phantom study, Measurement were performed on a area under the receiver operating characteristic curve (AUC) was 0.88. This Siemens Biograph mCT40 PET/CT using a NEMA IEC body phantom result is signifi cantly better than the results of CRP (76.47%,67.74%,0.72) containing different size six spheres fi lled with F18-FDG by applying or ESR(79.41%,58.06%,0.72). four signal to background ratios (4:1, 8:1, 10:1, 20:1). MTV of images Conclusion: The serum level of PTX3 was signifi cantly correlated with reconstructed four algorithms (OSEM3D, OSEM3D+PSF, OSEM3D+TOF, the infl ammatory activity of TKA detected by 18F-FDG PET/CT and its OSEM3D+PSF+TOF) were measured with different SUVmax threshold. quantitative relevance was much better than CRP or ESR. The diagnostic (30%, 35%, 40%, 45%, 50%, 55%, 60%). In patient study, we compared effi cacy especially sensitivity was also superior to that of CRP and ESR. MTV of tumor by applying different threshold of SUVmax in FDG PET PTX3 may better refl ect the severity of TKA and may be a potential images of 52 patients with lung cancer. To evaluate statistical analysis, biological marker to monitor the disease status of TKA. Wilcoxon test, Concordance correlation coeffi cient and Kruskal-Wallis test were performed. Authors listed for this abstract reported no relevant fi nancial disclosures. Results: In phantom, Overall, the use of increasing SUVmax threshold result in decreasing MTV.